Please find the agenda for the conference below. Speaker details will be updated throughout the run up to the conference.

Our programme has been built around three key themes. To find out which sessions fall into each theme, please click register now where you will be able to view this in more detail.

  • Future scanning
  • Technology
  • Guidance and evidence 
08:00 - 09:00 Registration and refreshments
09:00 - 09:20

Welcome from the Chair of NICE
Sir David Haslam, Chair, NICE

09:20 - 10:10

NICE futures

Over the last 20 years NICE has made a significant contribution to improving outcomes through its guidance standards and indicators, and has been at the heart of the drive for evidence-based care, adoption of innovative practice and giving people a voice in the health and care system. The opening plenary assesses the impact of this contribution and discusses the role NICE should play as it enters its third decade.

Chair: Dr Phil Hammond

Sir Andrew Dillon, Chief Executive, NICE​
Eric Low, Independent Healthcare Consultant and former CEO of Myeloma UK
Shirley Cramer CBE, CEO, RSPH

10:10 - 10:50

Prevention or pills?

How should we balance investment in public health programmes with transformative medicines to ensure that we have a sustainable, effective health service?

Chair: Dr Phil Hammond

Professor Yvonne Doyle, Regional Director London, Public Health England
Simon Nicholson,
Market Access Director for the UK, MSD

Gareth Arthur, Director of Strategy and Policy for Specialised Services, NHS England

10:50 - 11:30 Morning refreshments and networking  
11:30 - 12:25
Technology appraisals – fit for the future  Reliable evidence?: The roles of real-world data, patient evidence and randomised trials in judging treatment effectiveness Driving quality improvement in care
  • How NICE’s technology appraisals are responding to industry’s needs, including a discussion of managed access solutions and the new NICE commercial protocol, and NICE’s perspective on the Pharmaceutical Price Regulation Scheme.
  • Randomised trials have been the gold standard for evidence of effectiveness, but increasing numbers of patients with multiple conditions and the growing sophistication of real-world data offer new perspectives on how to decide what works and for whom.
  • Evidence-based quality improvement delivers real change and improvement. Here’s how, with examples from NICE Scholars.
Chair: Meindert Boysen, Director, Centre for Health Technology Evaluation, NICE Chair: Dr Phil Hammond Chair: Professor Gillian Leng, Deputy Chief Executive and Director of Health and Social Care, NICE
Carla Deakin, Programme Director, Commercial & Managed Access, NICE 
Leslie Galloway, Chairman, Ethical Medicines Industry Group
Blake Dark, NHS Commercial Medicines Director, NHS England
Professor Carl Heneghan, Director, Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford
Emily Lam, Lay member - Guidelines committee, NICE  
Dr Helen Macdonald, UK research editor, BMJ

Dr Roshelle Ramkisson, NICE Scholar; Child and Adolescent Consultant Psychiatrist; Psychiatry Programme Director, North West, Health Education England
Professor Graham Martin, Director of Research, The Health Improvement Studies Institute

Dr Tessa Lewis, General Practicioner and medical adviser, Chair NICE Managing Common Infections Committee

12:25 - 13:10
There’s an NHS approved app for that: the journey from digital concept to deployment Too much medicine? Getting the balance right NICE guidelines and standards for quality improvement: planning ahead for use in practice
  • What evidence should manufacturers provide, what should evaluators and commissioners look for and how can NICE and innovators collaborate to get ideas deployed quickly and effectively?
  • Some clinicians, researchers, patients and policymakers believe overdiagnosis and overtreatment are harming patients. We discuss the controversies around concerns about inappropriate prescribing.
  • Discover tools and resources from NICE to help you put our guidance into practice locally, learn how to keep your practice up to date with the latest evidence-based guidance and standards and understand how leaders at all level can drive change. 
Chair: Alexia Tonnel, Director of Evidence Resources, NICE Chair: Dr Phil Hammond Chair: Nicola Bent, Programme Director, System Engagement, NICE

Neelam Patel, Chief Operating Officer, MedCity
Mark Salmon, Programme Director Information Resources, NICE
Dr Asma Khalil, Consultant Obstetrician, St George’s Hospital London and Member, Quality Standards Advisory Committees, NICE

Dr Paul Chrisp, Director, Centre for Guidelines, NICE
Dr Samuel Finnikin, Clinical Research Fellow, Institute of Applied Health Research, University of Birmingham 
am Barnett-Cormack, Patient Advocate & Expert Patient
Nicola Thorley, Consultant Sexual Health and HIV, University Hospitals Birmingham NHS Foundation Trust and NICE Fellow   Deborah O’Callaghan, NICE implementation consultant, NICE 
Dr Joseph Hassell, Audley Health Centre
13:10 - 14:15 Lunch   
13:25 - 14:10 Optional NICE Field Team drop in sessions  
14:15 - 15:10
The long term plan for life sciences: managing the innovation pipeline Bringing genomics to the clinical frontline

Towards a learning health care system: accelerating the uptake of innovation and best practice – Dr Jennifer Dixon, Chief Executive, Health Foundation


  • The future of NICE healthtech assessments, how to identify innovations that the NHS needs and the latest developments and future role of HealthTech Connect.
  • The NHS is the first health system to offer whole genome sequencing, to be delivered through seven Genomic Laboratory Hubs. We will discuss how genomics will transform NHS care, and how the system should prepare.
  • Dr Jennifer Dixon’s experience ranges from medical practice to policy analysis and research. Using this, plus the learning from the wide range of projects funded by The Health Foundation across the UK, she will be discussing the state of quality of health care at present, and how improvements might occur faster at the clinical front line.
Chair: Mirella Marlow, Programme Director Devices and Diagnostics Systems, NICE Chair: Dr Phil Hammond In conversation with Richard Vize
Sheryl Warttig, Senior Technical Adviser, Centre for Health Technology Evaluation, NICE
Dr Sam Roberts, Director for Innovation and Life Sciences, NHS England

Doris-Ann Williams MBE, Chief Executive, BIVDA

Professor Clare Turnbull, Professor of Genomic Medicine and the Clinical Lead for Cancer Genomics for the 100,000 Genomes Project, Genomics England
Sarah Byron, Associate Director, Diagnostics Assessment Programme, NICE
Dr Jayne Spink, 
CEO, Genetic Alliance
15:10 - 15:50
Faster to Market Delivering mental health care – fit for the future Antimicrobial Resistance: Innovative models for the purchase of antimicrobials in the UK


How industry can be more agile and timely in getting innovations to patients

Chair: Meindert Boysen, Director, Centre for Health Technology Evaluation, NICE In conversation with Richard Vize Chair: Dr Phil Hammond
Dr Paul Catchpole, Value and Access Director, Association of the British Pharmaceutical Industry
Michael Seres, Founder, 11Health
David Baghurst, General Manager, NIHR Office for Clinical Research Infrastructure (NOCRI) and director of research programmes, National Institute for Health Research
Sarah Hughes, Chief ExecutiveCentre for Mental Health

Nick Crabb, Programme Director, Scientific Affairs, NICE 
Colm Leonard, Consultant Thoracic/Transplant Physician & Honorary Senior Lecturer, University Hospital of South Manchester NHS Foundation Trust; Consultant Clinical Adviser, NICE
Helen Scott, Head of Medicines Access and Policy, NHS England

15:50 - 16:20 Afternoon break and refreshments  
16:20 - 17:00

NICE: impact and future vision

NICE’s work has stimulated global interest in using evidence to inform judgments about value for money and effectiveness. The final session looks at advances in this field in the UK, US and worldwide, discusses how the adoption of new technologies and practices is managed and reveals NICE’s transformational plans to develop and present its work through agile, interactive and adaptable guidance pathways.

Chair: Dr Phil Hammond

Dr Steven Pearson, President, Institute for Clinical and Economic Review (ICER)
Professor Gillian Leng, Deputy Chief Executive and Director of Health and Social Care, NICE
Dr Julian Treadwell, GP; NIHR Doctoral Research Fellow, Nuffield Department of Primary Care Health Sciences, University of Oxford